Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.

A structure-guided hybridization approach using two privileged substructures gave instant access to a new series of tankyrase inhibitors. The identified inhibitor 16 displays high target affinity on tankyrase 1 and 2 with biochemical and cellular IC50 values of 29 nM, 6.3 nM and 19 nM, respectively, and high selectivity toward other poly (ADP-ribose) polymerase enzymes. The identified inhibitor shows a favorable in vitro ADME profile as well as good oral bioavailability in mice, rats, and dogs. Critical for the approach was the utilization of an appropriate linker between 1,2,4-triazole and benzimidazolone moieties, whereby a cyclobutyl linker displayed superior affinity compared to a cyclohexane and phenyl linker.

[1]  T. Pawson,et al.  Structural Basis and Sequence Rules for Substrate Recognition by Tankyrase Explain the Basis for Cherubism Disease , 2011, Cell.

[2]  H. Bregman,et al.  Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. , 2013, Journal of medicinal chemistry.

[3]  Brandoch D. Cook,et al.  Role for the Related Poly(ADP-Ribose) Polymerases Tankyrase 1 and 2 at Human Telomeres , 2002, Molecular and Cellular Biology.

[4]  D. Chin,et al.  Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. , 2013, Journal of medicinal chemistry.

[5]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[6]  M. R. Purnell,et al.  Novel inhibitors of poly(ADP-ribose) synthetase. , 1980, The Biochemical journal.

[7]  Bernhard Lüscher,et al.  Toward a unified nomenclature for mammalian ADP-ribosyltransferases. , 2010, Trends in biochemical sciences.

[8]  S. Krauss,et al.  Tankyrases as drug targets , 2013, The FEBS journal.

[9]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[10]  G. Drewes,et al.  Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. , 2013, Journal of medicinal chemistry.

[11]  S. Krauss,et al.  The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice , 2016, Diabetologia.

[12]  M. D. Lloyd,et al.  Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity. , 2017, Journal of medicinal chemistry.

[13]  Oliver Distler,et al.  Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis , 2012, Nature Communications.

[14]  Ryohei Katayama,et al.  APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer , 2017, Molecular Cancer Therapeutics.

[15]  Steve Schneider,et al.  Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. , 2013, ACS medicinal chemistry letters.

[16]  B. Shan,et al.  Human Cytomegalovirus Infection Dysregulates the Canonical Wnt/β-catenin Signaling Pathway , 2012, PLoS pathogens.

[17]  J. Behrens,et al.  The canonical Wnt signalling pathway and its APC partner in colon cancer development , 2006, Gut.

[18]  S. Krauss,et al.  Tankyrases: Structure, Function and Therapeutic Implications in Cancer , 2014, Current pharmaceutical design.

[19]  B. Durkacz,et al.  (ADP-ribose)n participates in DNA excision repair , 1980, Nature.

[20]  B. Durkacz,et al.  The effect of inhibition of (ADP-ribose)n biosynthesis on DNA repair assayed by the nucleoid technique. , 1981, European journal of biochemistry.

[21]  A. Ashworth,et al.  Tankyrase-targeted therapeutics: expanding opportunities in the PARP family , 2012, Nature Reviews Drug Discovery.

[22]  H. Dinh,et al.  Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. , 2011, Cancer research.

[23]  T. Pihlajaniemi,et al.  para‐Substituted 2‐Phenyl‐3,4‐dihydroquinazolin‐4‐ones As Potent and Selective Tankyrase Inhibitors , 2013, ChemMedChem.

[24]  H. Bregman,et al.  Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.

[25]  S. Krauss,et al.  A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. , 2013, Cancer research.

[26]  Steve Schneider,et al.  Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.

[27]  S. Krauss,et al.  Development and structural analysis of adenosine site binding tankyrase inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[28]  D. Chin,et al.  Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. , 2013, Journal of medicinal chemistry.

[29]  Tobias Karlberg,et al.  Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. , 2017, Journal of medicinal chemistry.